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The 2016 European Guidelines on cardiovascular disease prevention in clinical practice1 were the first 
major international guideline to address the potential uses of polypills (single dose formulations including 
a statin, anthihypertensives and aspirin), which is important because the first polypill has recently been 
launched throughout Europe. However, the Guidelines largely did not address the most obvious use of 
polypills – as a strategy to increase uptake and adherence to guideline-recommended medicines. Instead 
the Guidelines focused on a still-controversial use of polypills, in primary prevention for everyone over a 
certain age. Moreover, the need for cardiovascular endpoint trials was emphasized. This is a “straw man” 
approach: asking the question “should the polypill be given universally?”, rather than a much more 
relevant question “for what patients could currently available polypills provide worthwhile improvements 
in adherence?”.    
Elsewhere in the Guidelines the importance of providing statin, aspirin and BP lowering therapy to patients 
with CVD is emphasised, along with acknowledging the importance of adherence and the need for new 
strategies because current levels of adherence to cardiovascular medications are generally poor. A major 
intended use of the polypill is as a strategy to overcome these barriers to uptake and access to guideline 
recommended treatments – as reflected in many of the early publications2-4 and the majority of 
subsequent trials. We suggest that the discussion on the potential role of a polypill in improving adherence 
to cardio-protective drugs should be updated in the Guidelines in the light of additional evidence. This 
article attempts to provide a suggested framework for considering the randomized evidence, and 
discusses when a cardiovascular endpoint trial should and should not be required. With the guidelines due 
for review and updating in 2019shortly, and additional trial evidence available, it is timely to reconsider 
the polypill narrative within the guidelines. 
   
Suggested criteria use cases for discussing usesupdating the evidence for of the polypill in CVD 
prevention  
The guidelines currently note publication of a recent meta-analysis5 showing improved risk factor levels 
with use of a polypill, however criticize this meta-analysis as having multiple comparators and diverse 
composition and doses of included polypills. The rationale behind the various polypill trials conducted 
thus far has varied from establishing short-term effects on risk factors and side effects of polypills vs 
placebo thus demonstrating efficacy and safety of the product, through to establishing effectiveness 
against usual care of these patients within pragmatic trial settings. The type of patient targeted by each 
trial has also varied including secondary prevention,6,7 high-risk primary prevention7,8, and age over 55 
years.9   This explains the diversity of comparators. And the diversity of doses and agents is to be expected 
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– there are millions of permutations of recommended drugs, and so it is to be expected there will be 
numerous polypill versions.  
 
Along with other colleagues wWe suggest that it would be useful to consider the potential benefit and the 
scientific evidence for use of polypills in four distinct potential areastwo distinct patient groups:   
1. Established indications for all polypill medicines (ie. Guidelines and approved labels recommend 
drugs should be used in this patient group), patient taking drugs already as separate pills. This use 
can be called “established indications, straight substitution”   
2. Established indications for all polypill medicines, but not taking them all due to barriers in uptake 
and/or adherence. This use can be called “established indications, step-up substitution”, since 
patients who are taking some but not all therapy (eg. aspirin and statin but no blood pressure 
lowering) stop that therapy (at least the aspirin and statin component) and are switched to a 
polypill containing aspirin, statin and blood pressure lowering.  
3. Established indications for some of the polypill medicines, and patient-level prediction that 
absolute benefits will exceed risks – “high risk primary prevention”. In this use, all patients would 
have a raised risk of cardiovascular disease, as a result of a constellation of clinical conditions 
and/or a high global cardiovascular risk score, and would be treated with the polypill as a global 
risk reduction strategy in which it is expected that benefits would exceed side effects. This might 
include use of some component medicines in a way that did not match current approved labels 
(eg. aspirin for patients without symptomatic atherosclerotic vascular disease, blood pressure 
lowering for patients without hypertension)  
4. No established indications, but estimation that individual and population-level benefits will be 
worthwhile eg. a strategy to provide polypills to everyone aged over >55yrs. No drug has a 
registered indication of “age >55 years” and so this use would be in addition to currently approved 
labelling.   
  
The guidelines currently note publication of a recent meta-analysis5 showing improved risk factor levels 
with use of a polypill, however criticize this meta-analysis as having multiple comparators and diverse 
composition and doses of included polypills. The reason for the disparity of comparator groups and patient 
populations was because different trials were testing different use indications. The rationale behind the 
various polypill trials conducted thus far has varied from establishing short-term effects on risk factors 
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and side effects of polypills vs placebo (mostly with relevance to uses 3 and 4 above), through to 
establishing effectiveness against usual care of these patients within pragmatic trial settings (testing uses 
1 and 2 above). The type of patient targeted by each trial has also varied including secondary prevention,6,7 
high-risk primary prevention7,8, and age over 55 years.9   This explains the diversity of comparators. And 
the diversity of doses and agents is to be expected – there are millions of permutations of recommended 
drugs, and so it is to be expected there will be numerous polypill versions.  
  
Evidence for improved adherence with use of polypills in patients with established disease or at high 
risk vs moderate risk primary preventionindications for component drugs.  
The 2016 guidelines noted that only two trials6,10 have shown improved adherence in patients with 
established indications  - this requires updating considering a large and clinically relevant improvement in 
adherence has been seen in four trials now, UMPIRE, IMPACT, Kanyini-GAP and FOCUS (Figure).6,10-12 Of 
note, the polypill used in the FOCUS trial contained different blood pressure lowering component 
(Ramipril at difference doses) to the polypill used in the other 3 trials (combination of lisinopril and 
hydrochlorothiazide, or lisinopril and atenolol). The FOCUS trial assessed the 1st use indication and 
randomized 695 patients with CHD to polypill-based care or treatment with the same drugs as three 
separate pills.6 At 9 months’ follow-up they observed a 10% absolute increase in adherence in the 
intervention group compared to the control group (65.7% vs 55.7%, p=0.012). The authors concluded that 
polypills could be of use to improve adherence to recommended medications in secondary prevention 
after myocardial infarction. The SPACE trials10-12  (3140 patients with CVD or high risk, testing polypill-
based care vs usual care) tested the polypill in uses 1 and 2 ie. Straight and step-up substitution. The 
comparator in these trials was usual care with no restrictions resulting in a range of different medication 
regimes in the usual care arm. Meta-analysis of these three SPACE Collaboration trials confirmed 
improvement in adherence of 30% for polypill based care compared to usual care (regardless of usual care 
regimen used).7 The benefits were considerably larger for step-up substitution than for straight 
substitution. There were also corresponding improvements in SBP and LDL cholesterol levels over 12 
months of 2.5 mmHg (95% CI -4.5 to -0.4mmHg; p=0.02) and 0.1 mmol/L (95%CI -0.2 to 0.0; p=0.04) 
respectively when polypill use was compared with usual care, despite the wide variety of usual care 
regimes that were utilized and the potential to ‘tweak’ therapy to maximize outcomes in that arm. . 




Within all these trials no excess of side effects was seen outside of the components’  well-established 
safety profiles.13 The Guidelines currently state “potential adverse effects of a single drug component of 
the FDC cannot be specifically corrected and therefore may also affect treatment adherence to the other 
components” however we suggest that all four of these trials were specifically designed to evaluate the 
balance of any benefits from improved adherence with any unintended adverse consequences – and 
consistently showed that the adherence benefits were sufficiently large to outweigh the potential 
problems of fixed-dose combination approach.     
  
We suggest that this provides sufficient evidence to confirm that use of polypills in patients with 
established disease or at high risk of developing CVD improves adherence to recommended CVD 
preventive medications with consequent improvement in CVD risk factor levels. Recommended 
medications for CVD prevention may change over time with changing evidence (e.g. recent updates to 
aspirin recommendations in primary prevention). For clarity, we are proposing that the concept of fixed 
dose combinations (polypills) containing guidelines recommended therapies (currently statins, blood 
pressure lowering agents and anti-platelet therapy for secondary prevention and some high risk primary 
prevention) be considered part of the armamentarium of the clinician in managing CVD risk. 14 
  
The need for CV endpoint trials  
The Guideline ends with the statement that “Until we have the results of ongoing trials with major CVD as 
the endpoint, the polypill cannot be recommended for prevention of CVD and cannot be prescribed to all 
individuals.”  However, this only addresses one possible role of the polypill. As a tool to increases 
adherence to guideline-recommended treatments, it is not necessary or appropriate to “re-require” 
evidence of benefit on CV endpoints. Fixed dose combinations in many areas, such as HIV/AIDS and TB, 
have not been required to re-demonstrate the benefits already established for individual agents. Blood 
pressure combination drugs are not required to repeat the endpoint trials conducted for their 
components – it is now considered sufficient for the guidelines to recommend that clinicians consider 
prescribing dual combination therapy as initial therapy for hypertension to improve compliance. We 
suggest that the combination of statins, blood pressure lowering and aspirin should not be any different. 
We do however suggest endpoint trials may be required if the polypills are used in patient populations 
beyond those who have existing approved indications, such as in patients at moderate risk or using age 
based inclusion criteria, such as uses 3 and 4 above. A large high-risk primary prevention trial is ongoing 
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(TIPS3) funded by The Wellcome Trust, Canadian Institutes of Health Research and Heart and Stroke 
Foundation of Ontario and this will provide additional evidence as to the risk-benefit ratio of polypills in 
this populationpatients without established indications for component therapy. Although highly 
persuasive arguments can be mounted that the evidence for individual components is overwhelming, 
including evidence of benefit in the presence of other components, the key factor is that drug regulations 
do not currently allow such usage until new supportive clinical trial evidence is provided.  
  
Conclusion  
There is now a polypill available throughout Europe – Trinomia® containing atorvastatin, ramipril and 
aspirin. Additional polypills containing different blood pressure components are also likely to be launched, 
and some combination therapies without aspirin (e.g. Triveram®) for patients with a contraindication for 
aspirin are also now on the market. The Guidelines have an important opportunity to guide clinicians on 
the potential role of this new strategy to help patients and prescribers reach guideline goals.  A consistent 
high level of patient and prescriber acceptability has been demonstrated for polypills as a strategy to 
improve adherence to guideline-recommended therapy.15 We support the revision of the guidelines to 
include recommendations around the use of the polypill as a tool to improve adherence in those with 
established indications for aspirin, statin and blood pressure lowering therapy and more broadly for 
combination therapy containing statin and blood pressure lowering medication.  
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Figure 1. Proportion of trial participants adherent to combination therapy at end of study in 
participants with either established CVD or at high calculated risk. Adherence defined as taking 
antiplatelet, statin and ≥ 2 BP lowering drugs at least 4 days of the last 7 at end of study in 
UMPIRE10, Kanyini-GAP11 and IMPACT12. Adherence defined in the FOCUS6 trial as pill count 
between 80 and 110% at end of study plus a score of 20/20 on the Morisky-Green questionnaire. 
 
